Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice. by Gibson, S. L. et al.
Br. J. Cancer (1994), 69, 473 481 t. Macmillan Press Ltd., 1994
Effects of photodynamic therapy on xenografts of human mesothelioma
and rat mammary carcinoma in nude mice
S.L. Gibson', T.H. Foster2, R.H. Feins3, R.F. Raubertas45, M.A. Fallon6 & R. Hilf'5
'Department ofBiochemistry, 2Department ofRadiology, 3Department ofSurgery, 4Department ofBiostatistics, 5Cancer Center
and 6Department ofPathology, University ofRochester, School ofMedicine and Dentistry, Rochester, New York 14642, USA.
Summary We have examined the effectiveness of photodynamic therapy against R3230AC rat mammary
adenocarcinoma and human mesothelioma as xenografts in the same host. The results demonstrate that the
xenografted human tumour is significantly more responsive to photodynamic treatment than the rodent
mammary tumour. Studies also showed that the mesothelioma xenograft was fluence rate- and fluence-
dependent while the rat tumour exposed to the same conditions demonstrated neither of these dependencies.
This disparity in response was not attributable to a difference in either whole-tumour uptake or subcellular
distribution of the porphyrin photosensitiser. Analysis of the effects of visible irradiation on cytochrome c
oxidase activity, measured in mitochondria prepared from tumours borne on hosts injected with photosen-
sitiser, demonstrated that photoradiation-induced enzyme inhibition was significantly greater in mesothelioma
than in R3230AC mammary tumour preparations. However, in parallel studies conducted in vitro, when
photosensitiser and light were delivered to previously unperturbed mitochondria, rates of enzyme inhibition
were not significantly different. Both tumours were established in long-term cell culture. While the uptake of
porphyrin photosensitiser was equivalent in both cell lines, the R3230AC cells displayed a significantly greater
photosensitivity than the mesothelioma cells. The data presented here demonstrate that the mechanisms that
govern response to photodynamic therapy are complex, but in the case of these two xenografted tumours host
response to therapy is not likely to play a significant role.
Diffuse malignant mesothelioma (DMM) occurs on the
serosal surfaces of the body. Induction of DMM is associated
with prolonged exposure to asbestos fibres, followed by a
latency period of 15-30 years before appearance of symp-
toms that support its diagnostic confirmation (Wagner et al.,
1960; McDonald & McDonald, 1980; Muscat & Wynder,
1991). The disease presents as a sheet of malignant cells,
usually containing scattered nodules up to 1 cm in diameter
at the time of diagnosis. Conventional therapies fail to arrest
DMM and death by suffocation occurs within 6 months to 2
years (Law et al., 1984; Alberts et al., 1988).
Photodynamic therapy (PDT) is demonstrating efficacy
against various human malignancies, including lung, bladder,
oesophagus and breast. This therapy consists of systemic or
topical administration of a photosensitiser, such as Photofrin
Porfimer Sodium (PPS), followed by exposure of lesions to
visible light 24-72 h after injection of photosensitiser. This
regimen has evolved to take advantage of the reported
preferential retention of specific porphyrins in tumour tissue
(Gomer & Dougherty, 1979; Woodburn et al., 1992). The
light is usually delivered via fibre optics coupled to the
output of a tuned dye laser. The resulting electronic excited
state of the porphyrin retained in tumours initiates a
photochemical reaction, which in turn forms the toxic oxygen
species, singlet oxygen ('02) (Weishaupt et al., 1976; Gibson
et al., 1984; Keene et al., 1986). Intracellular oxidative
damage induced by '02 occurs in lipid-rich cellular structures,
such as the plasma, mitochondrial and ribosomal mem-
branes, where accumulation of PPS is greatest because of the
hydrophobic nature of its 'active' components (Moan et al.,
1982; Kessel & Cheng, 1985; Dougherty & Mang, 1987). The
'02-induced damage leads to reduced cellular metabolism,
morphological alterations, cytotoxicity and tumour necrosis
(Hilf et al., 1986, 1987; Berg & Moan, 1988).
DMM, owing to its anatomical location and morphology,
is a potential candidate for PDT. Pass et al. (1990) have
undertaken phase II clinical trials of PDT for mesothelioma,
and results are encouraging, as are those obtained by T.
Mang (personal communication), who have recently demon-
strated the efficacy of PDT for this disease. Ris et al. (1991)
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treated four patients with PDT using a chlorin derivative and
obtained positive responses in three. Perry et al. (1990) and
Keller et al. (1990) found that mesothelioma cells in culture
were sensitive to PDT using PPS. Employing meta-tetra-
hydroxyphenylchlorin (mTHPP), Ris et al. (1993) found that
a 3 day interval between sensitiser administration and
exposure of mesothelioma tumours in nude mice was
optimum for response to PDT with this chlorin. In our
laboratory, xenografted tumours, arising from H-MESO-1
cells implanted in nude mice, responded favourably to PDT,
displaying drug-, fluence rate- and fluence-dependent rela-
tionships (Feins et al., 1990), with many animals remaining
tumour free for 30 or more days.
These findings, when compared with the less striking re-
sponse we had observed for a rat mammary adenocarcinoma
(Gibson et al., 1990; Foster et al., 1991), led us to enquire
whether the sensitivity of this human mesothelioma tumour
xenograft was due to intrinsic properties of the host or to
inherent sensitivity of the tumour. To address this, we com-
pared the response to PDT of the human mesothelioma with
that of the rat tumour model in the same host, the nude
mouse. We also assessed the uptake of '4C-labelled
polyhaematoporphyrin (PII) in whole-tumour homogenates
and subcellular fractions and the effect photosensitisation
might have on a selected biochemical end point.
Materials and methods
Chemicals
Photofrin Porfimer Sodium (PPS, lyophilised), a gift from
Quadralogic Technologies (Vancouver, BC, Canada), was
dissolved in sterile 5% dextrose solution, divided into 1 ml
aliquots and stored at -70°C until used. ['4C]Polyhaemato-
porphyrin ([`4C]PII, 1 Ci mol 1), a material stated by the
supplier to be similar in composition and biological activity
to PPS (formerly Photofrin II, Pll), was purchased from
Leeds Radioporphyrins (Leeds, UK). This lyophilised prepar-
ation was solubilised in 5% dextran (1.2 ml) such that a final
sensitiser concentration equivalent to 2.5 mgml-' at
4gCiml-' was attained, and 0.1 ml aliquots were frozen at
- 70°C until used. All other chemicals and reagents were
purchased from Sigma (St Louis, MO, USA).
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Animals and tumours
Mesothelioma tumours were produced in the flanks of
athymic nude mice (Ncr-nu) by subcutaneous implantation of
0.2 ml of a suspension of H-MESO-1 cells (5 x 106) obtained
from Mason Research Labs (Worcester, MA, USA).
Tumours grew to approximately 1 cm in diameter within 30
days of implantation. Subsequently, mesotheliomas were pro-
pagated by incisional implantation of 1 mm3 slices into the
flanks of nude mice anaesthetised with halothane. Serial
transplantations were limited to five passages with tissue that
had been previously frozen at - 70°C from passages 1 and 2.
Histological examination was performed on randomly
selected tumours at various passages in a single blind test by
a veterinarian pathologist. All the samples analysed were
determined to be mesothelioma.
The R3230AC mammary carcinoma, obtained from
Fischer 344 female rats, was also implanted subcutaneously
in the flanks of nude mice by the incisional technique de-
scribed above. The R3230AC tumour in the nude mouse was
always used as a primary implant obtained from serially
transplanted donor rats. Data presented for R3230AC mam-
mary carcinomas in the rat are from previous studies (Gibson
et al., 1990; Foster et al., 1991). All animals received care
according to the guidelines of the University Committee on
Animal Resources at the University of Rochester.
PDT treatment conditions
Nude mice bearing either the H-MESO-1 mesothelioma or
R3230AC tumours received 5 mg kg-' PPS intraperitoneally
when tumours reached 0.5-0.6 cm diameter (0.1-0.17 cc),
usually 12-18 days after implantation. Twenty-four hours
after injection of PPS, animals were anaesthetised with
75mgkg-' Ketalar (Parke Davis) and 6mgkg-' Rompun
(Butler). Tumours were exposed transdermally to 630 nm
laser irradiation (Inova 90 argon pumped dye laser, Cohe-
rent, Palo Alto, CA, USA) delivered via a fibre optic fitted
with a cylindrical lens to provide a 1-cm-diameter light field.
Light was delivered continuously using various power den-
sities and total fluences; 200mWcm-2 for 30 min = 360 J cm-2
or at 50mWcm-2 for 30, 60, 90 or 120 min to give 90, 180,
270 or 360 J cm-2 respectively. Light was also delivered using
a fractionated regimen (100 mW cm-2 for 2 h at 30 s on/30 s
off), which produced the best response for the R3230AC
tumour in rats (Foster et al., 1991). Tumours were measured
through the skin with calipers prior and subsequent to PDT;
tumour volumes were calculated using the equation for a
cylinder, V = 7r2H, where r is half of the width and H is the
longer dimension.
Statistical analysis
Tumour growth was compared among various treatment
groups by applying the log-rank test to tumour doubling
times: the number of days required for tumours to double
their initial, pretreatment volume. Some animals are included
whose tumours did not reach 2 x initial volume prior to
cessation of measurements; some were sacrificed because of
morbidity unrelated to tumour burden and some attained
their expected lifespan and died without tumour recurrence
or volume doubling, i.e. 'cures'. Exact, small-sample P-values
for the tests were computed using the program STATXACT
(Cytal Software, Cambridge, MA, USA). All other statistical
analyses were performed using the Student's t-test. For all
tests, a two-sided P-value of less than 0.05 was considered to
be a statistically significant difference.
['4C]Polyhaematoporphyrin administration and tissue
distribution
['4C]Polyhaematoporphyrin (['4C]PII), prepared as above, was
thawed on ice, brought to room temperature and injected i.p.
into 20 g nude mice at a dose of 5 mg kg-' containing
0.1 ltCi per mouse. Portions of liver, lung, heart,
mesothelioma or R3230AC tumour were excised at selected
times, weighed and placed in scintillation vials. Protosol
(NEN, Boston, MA, USA) was added (1:10, w/v) and the
tissue was finely minced with scissors. The tissue mince in
Protosol was incubated in a shaking water bath (Aquatherm,
New Brunswick Scientific, New Brunswick, NJ, USA) at
50°C for 12-16 h. One millilitre of Protosol containing dis-
solved tissue was transferred to a fresh scintillation vial.
After addition of 0.1 ml of 30% hydrogen peroxide, the
mixture was shaken in the water bath at 50°C for 30 min to
decolorise the samples. After cooling to room temperature,
10 ml of Aquasol (NEN, Boston, MA, USA) was added, and
each vial was vigorously agitated. Samples were stored in the
dark at room temperature for 1 or 2 weeks to reduce
chemiluminescence and obtain stable counts. Radioactivity
was assessed in a Beckman LS5O00OTD liquid scintillation
system (Beckman Industries, Fullerton, CA, USA). Tissue
samples from mice not given ['4C]polyhaematoporphyrin
were treated as above with no detectable difference in back-
ground counts being observed amongst the various tissues.
['4C]Polyhaematoporphyrin distribution in mitochondrial
preparations
Animals bearing either mesothelioma or R3230AC tumours
were administered 6.25 mg kg-' ['4C]PII (0.25pCi) i.p.
Tumours and livers were surgically excised 24 h later, tissues
homogenised and mitochondria prepared using a modified
procedure of Gibson and Hilf (1983). Briefly, the
homogenate was prepared by weighing 2 g of tissue and
adding 5 ml of buffer containing 0.33 M sucrose, 1 mM
dithiothreitol, 1 mM EGTA, 0.03% bovine serum albumin
and 100 mM potassium chloride. Tissues were homogenised
on ice using a Polytron (PCU2-110; Brinkmann Industries,
Westbury, NY, USA) at a setting of 6 for two 30 s bursts.
An aliquot of 200fsl was removed from this preparation and
stored at - 70°C until prepared for counting. The remaining
homogenate was centrifuged at 800g for 15 min at 4°C (PR-2
International Centrifuge, Needham Heights, MA, USA);
200 lI of this supernatant and the pellets were saved and
frozen for subsequent counting. The remaining supernatant
fraction was centrifuged at 8,000g (J-21, Beckman Industries,
Palo Alto, CA, USA), and the supernatant from this step
was collected, frozen and stored. The pellet from this 8,000g
centrifugation was resuspended in 2 ml of buffer and cen-
trifuged at 15,000g. The supernatant and the mitochondrial
pellets, which were resuspended in 2 ml of buffer, were saved
and stored at -70°C until prepared for scintillation count-
ing. Total protein analysis was performed on each sample
using the method of Lowry et al. (1951). Samples were
thawed at room temperature and 0.1 ml added directly to
4ml of Ecoscint A (National Diagnostics, Mannville, NJ),
vortexed vigorously and allowed to stand for 24 h prior to
assessment of radioactivity.
In vivo-in vitro measurement ofcytochrome c oxidase
Separate groups of animals bearing either the R3230AC or
mesothelioma tumours received 5 mg kg-' PPS i.p. 24 h prior
to surgical excision of lesions and preparation of mitochond-
rial suspensions as described previously (Gibson & Hilf,
1983). Aliquots of 1 ml of mitochondria were transferred to
3 ml quartz cuvettes and subsequently exposed to filtered
(570-700 nm) and focused (1 cm diameter) quartz halogen
irradiation deliyered at 150 mWcm2. The suspensions were
stirred continuously, and 10 Iil samples were removed at
selected times and analysed for cytochrome c oxidase activity
as described previously (Gibson & Hilf, 1983). The
temperature in the cuvette was monitored during the irradia-
tion period and did not rise above ambient.
In a parallel set of experiments to determine the intrinsic
sensitivity of mesothelioma or R3230AC mitochondria to
PPS photosensitisation, mitochondria were prepared from
tumours borne in untreated animals following the above
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dark with intervals of mixing. Suspensions were centrifuged
at 8,000 g using a microcentrifuge (B. Hermle, Germany), the
supernatant discarded, mitochondria resuspended in 1 ml of
buffer, irradiated with broad-band light and cytochrome c
oxidase activity measured as above. Protein measurements of
mitochondrial suspensions were performed according to the
method of Lowry et al. (1951).
Uptake andphototoxicity ofporphyrin in tumour cells in
culture
In order to determine whether there was any difference in the
uptake of phototoxicity of porphyrin in either mesothelioma
or R3230AC cells in culture, xenograft tumours were sur-
gically excised and single-cell suspensions made according to
the dissociation procedure described previously (Hissin &
Hilf, 1978). Cell lines were established and maintained in
continuous passage culture using a-MEM plus 10% fetal
bovine serum (Gibco, Grand Island, NY, USA). For experi-
ments, cells from passage 10 or less were seeded in 12 well
plates at 1.5 x 105 cells per well and allowed to attach for
24 h in a 5% carbon dioxide incubator at 37°C (Forma
Scientific, Marietta, OH, USA). Cells were counted and PPS
at various concentrations was added for 24 h in the dark at
37°C. Medium containing PPS was then removed, cells were
washed with 0.9% saline, 1 ml of MEM without phenol red
was added to the wells, and monolayers were irradiated with
unfiltered 14 W fluorescent light 6 cm from the surface of the
well, which provided an incident fluence rate of 0.2 mW cm-2.
The MEM without phenol red was replaced with a-MEM
plus 10% FBS, and cells were incubated for 24 h at 37°C in
the dark. Cells were then trypsinised and counted using a
particle counter (Coulter ZM, Coulter Electronics, Hialeah,
FL, USA). Data are expressed as the cell number obtained
from cultures irradiated in the presence ofPPS expressed as a
percentage of control (cells plus PPS not irradiated or
irradiated cells minus PPS).
Uptake of ['4C]PII into cultured tumour cells was
estimated using cultures parallel to those above by adding
various concentrations of [14C]PII and incubating cells in the
dark for 24 h. The medium containing labelled material was
removed, cells were trypsinised with 0.2 ml of trypsin and
radioactivity counted 24 h after transfer to 4 ml of Ecoscint,
using the equipment described above.
Histologicalpreparation and light microscopy
The freshly excised tumours and their adjacent soft tissue
were immediately placed on ice and examined. Tumour size
and gross morphological features were recorded. Specimens
were grossly cross-sectioned at 1-2 mm intervals and serially
labelled. When enough tissue was available, representative
sections were snap frozen at -70°C for future use. Material
for light microscopic analysis was fixed in 10% neutral-
buffered formalin for 20-24h, processed on a Tissue-Tek
automated processor, paraffin embedded, and sectioned at
61tm intervals. Multiple serial sections throughout the
tumour mass were stained with haematoxylin and eosin or
Masson trichrome and examined by light microscopy.
Results
Effect ofPDT on growth ofmesotheliomas or R3230AC
tumours in the nude mouse
The response of mesothelioma or R3230AC xenografts to
PDT was studied using a variety of irradiation protocols
delivered 24 h after administration of 5 mg kg-' PPS. All
PDT light treatments applied to either neoplasm produced
significant delays (P<0.004) in tumour volume doubling
time compared with untreated controls (no treatment, group
1; Tables I and II).
Analyses of the tumour growth data for treatment of
mesotheliomas by PDT (Figure la and Tables I and III)
demonstrated fluence dependence when light was delivered
at a fluence rate of 50 mW cm2; there was a significant
increase in tumour volume doubling time when 90Jcm-2
was compared with 180Jcm-2, and a nearly significant in-
crease (P = 0.053) from 180 J cm-2 to 270 J cm-2 total
fluence, while no difference was observed when 270 was
compared with 360 J cm-2. All light treatments delivered
continuously at this dose rate, i.e. 50 mW cm2, except for
animals that received a total fluence of 90 J cm-2, produced a
delay in mesothelioma growth that was significantly greater
than that seen in animals receiving a total fluence of
360 J cm-2 delivered at a rate of 200 mW cm-2. Similar rela-
tionships between extent of tumour growth delay and fluence
rate or total fluence were not as evident for the R3230AC
xenografts exposed to PDT (Figure lb and Tables II and
III). Although all light treatment protocols provided
significant delays in tumour growth when compared with
controls, no fluence rate or total fluence dependence was
detected for the R3230AC tumour when intercomparisons of
irradiation protocols were analysed. Comparisons of the
effects of PDT on mesothelioma vs R3230AC xenografts,
however, showed significantly greater control of the
mesothelioma for all the total fluences except 180 J cm-2
when light was delivered at 50 mW cm-2 or when 360 J cm-2
was applied using the fractionated protocol with a fluence
Table I Response of mesothelioma tumours to PDT
Response
Irradiation Number of tumours
Fluence rate Fluence Days to double initial volume doubling out of Mediana
Group (mWcm2) (Jcm-2) (number of mice) total (days)
1 0 0 1(4), 2(3), 3(7), 4(3), 5(1), 7(3) 21/21 3
2 200 360 9(2), 13(1), 17(1), 21(1), 23(1), 7/9 21
25(1), 28b(2)
3 50 90 5(1), 11(1), 12(1), 15(1), 17(2), 7/7 15
25(1)
4 50 180 21(1), 30(1), 31(1), 44(1), 55(1), 5/7 44
58b(1), 70b(l)
5 50 270 44b(2), 46b(I) 64b(l), 84b(l) 0/5 >46
6 50 360 26b(l), 28(1), 33b(l), 37b(l) 1/11 >40
38b(1), 40b(3), 44b(1), 61b(l),
69b(l)
7 100 360c 49(1), 195(1), 208b(1), 237b(l), 2/7 >237
278b(1), 280b(I), 37lb(l)
aMedian number ofdays for tumours to reach twice initial volume. Values are expressed as greater than for groups
in which fewer than half of the tumours were observed to double in volume. bNumber ofpost-treatment observation
days for tumours that did not double in volume. cfrfadiation fractionated at 30 s on/30 s off (see Materials and
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Table n Response of R3230AC tumour xenografts to PDT
Response
Irradiation Number of tumours
Fluence rate Fluence Days to double initial volume doubling out of Mediana
Group (mW cm2) (Jqcm-2) (number of mice) total (days)
1 0 0 2(4), 3(5), 4(4) 13/13 3
2 200 360 13(1), 15(2), 17(1), 19(1), 29(1) 6/6 16
3 50 90 4(1), 7(1), 8(2), 10(1), 12(1) 6/6 8
4 50 180 7(1), 8(1), 12(1), 13(1), 14(1), 5/8 14
14b(3)
5 50 270 3(1), 5(2), 12(2), 17(1), 21(1) 7/7 12
6 50 360 2(1), 3(1), 4(1), 5(1), 12(1), 12/12 15
15(1), 16(2), 17(1), 18(2), 44(1)
7 100 360c 11(1), 16(1), 18(1), 20(1), 31(1), 7/7 20
36(1), 38(1)
aMedian number of days for tumours to reach twice initial volume. bNumber of post-treatment observation days
for tumours that did not double in volume. CIrradiation fractionated at 30 s on/30 s off (see Materials and methods).
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Figure 1 Effects of PDT on the growth of mesothelioma (a) or
R3230AC (b) tumours implanted in the flanks of nude mice. Data
represent the percentage of tumours that reached twice the initial
pretreatment volume. The groups in a (mesothelioma) and b
(R3230AC; see Tables I and II) are control, no PPS, no light
(no. 1, 0), or treatment groups in which light was delivered at
200 mW cM-2 for 30 min = 360 J cm-2 (no. 2, 0), at
50 mW cm-2 for 30, 60, 90 or 120 min equalling 90 (no. 3, A),
180 (no. 4, U), 270 (no. 5, *) or 360 Jcm2 (no. 6, A) or at
100 mW cmn2 for 2 h = 360 J cm2 fractionated with 30 s on and
30 s off intervals (no. 7, X). All tumour-bearing animals in the
treatment groups were injected i.p. with 5 mg kg- PPS 24 h prior
to exposure of lesions to visible laser light.
rate of 100 mW cm-2. The observed difference in response of
these two xenografts to the various PDT light regimens
suggests that certain intrinsic properties of neoplasms may be
important determinants of the efficacy of PDT.
Uptake and retention of[4C]polyhaematoporphyrin in tumour
and normal tissues
One possible explanation for the enhanced tumour response
of mesothelioma vs R3230AC xenografts could be a
difference in the amount of porphyrin retained in these
tumours. To address this, we examined ['4C]PII uptake and
retention in tumours and in selected normal tissues from
mice bearing either tumour type, so as to eliminate any bias
attributable to the presence of one tumour or the other. The
data (Figure 2) show that there were decreases in radioac-
tivity over a 48 h period in liver, heart and lung tissue. The
radioactivity in mesothelioma and R3230AC xenografts did
not change significantly during the same time course. Skin,
however, displayed an increase in radioactivity in samples
taken at 24 or 48 h after [14C]PII was injected when com-
pared with the 4 h time point. Thus, both tumour xenografts
accumulated and/or retained similar amounts of '4C-labelled
porphyrin, whereas normal tissues displayed a greater diver-
sity in the patterns of uptake and release of PII during the
time course studied.
In vivo uptake of[4C]polyhaematoporphyrin into tumour and
liver mitochondria
Although there was no difference in the total amount of
radioactivity found in mesothelioma or R3230AC tumour
homogenates, it is possible that the subcellular distribution of
sensitiser could differ between these tumours and that this
might offer an explanation for the differences in their res-
ponse. To examine this possibility, we used differential cent-
rifugation to determine the amount of radiolabelled por-
phyrin present in subcellular fractions of both xenografts and
liver obtained 24 h after injection of[14C]PII in vivo. The data
summarised in Table IV demonstrate that there was no
significant difference in the radioactive content of any of the
subcellular fractions when the two tumour preparations were
compared after undergoing the same differential centrifuga-
tion procedures. These data indicate that subcellular distribu-
tion of [14C]PII components was equivalent for both tumours
and should not account for the difference in response of these
xenografts to PDT. The protein content of each subcellular
fraction from the two xenografts was almost identical. It is
interesting to note that the data in Table IV demonstrate that
the accumulation of radiolabelled porphyrin in liver
mitochondria was about 2-3 times that found in the whole-
liver homogenate indicating that liver mitochondria concent-PHOTODYNAMIC THERAPY OF TUMOUR XENOGRAFTS 477
Table III S,tatistical analysis of tumour response to PDT
Mesotheliom (I) vs
Mesothelioma (I) R3230AC (II) R3230AC (II)
Groups P-values Groups P-values Groups P-values
aI-I vs 1-2 to I-7 All 0.0001b II-1 vs II-2 to 11-7 <0.0042 I-I vs II-1 0.4435
1-2 vs I-3 0.1795 II-2 vs II-3 0.0022 I-2 vs 11-2 0.6102
I4 0.0411 I14 0.1792 1-3 vs 11-3 0.0256
1-5 0.0210 11-5 0.1760 14 vs 114 0.0740
I-6 0.0011 11-6 0.5442 1-5 vs II-5 0.0025
1-7 0.0040 11-7 0.1457 1-6 vs 11-6 <0.0001
1-7 vs 11-7 0.0003
1-3 vs 1-4 0.0012 11-3 vs II-4 0.0286
1-5 0.0025 II-5 0.3019
1-6 0.0001 11-6 0.1013
1-7 0.0006 II-7 0.0023
14 vs I-5 0.0530 II-4 vs 11-5 0.4283
I-6 0.0450 11-6 0.7507
I-7 0.0210 II-7 0.1803
I-5 vs 1-6 0.9176 11-5 vs II-6 0.6674
1-7 1.0000 II-7 0.0344
I-6 vs 1-7 0.7190 II-6 vs 11-7 0.1706
Values appearing in bold type designate those comparisons that were significant, P <0.05. aI,
mesothelioma; II, R3230AC, arabic numbers 1-7 are light treatment protocol groups from Tables I and II.
bSignificance determined using the log-rank test (P-values) as described in Materials and methods.
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Figure 2 Uptake of '4C-labelled Pll into various tissues at 4, 24
or 48 h after i.p. administration (see Materials and methods).
Radioactivity is presented as d.p.m. per 100 mg of tissue,
mean ± s.e.m.
rate ['4C]PII. Taken together, these data do not implicate
differences in subcellular localisation of ['4C]PII as the basis
for the greater sensitivity of mesothelioma xenografts to
PDT.
Effects ofPDT on mitochondrial cytochrome c oxidase in vivo
and in vitro
The effect ofphotosensitisation on the activity of cytochrome
c oxidase was measured in tumour mitochondria (obtained
and isolated 24 h after administration of PPS, 5 mg kg-') by
exposing mitochondrial suspensions to visible irradiation in
vitro. We previously demonstrated that cytochrome c oxidase
activity in mesothelioma tumour homogenates was photosen-
sitised to the greatest extent at 24-48 h after PPS injection
(Feins et al., 1990). Therefore, we selected 24 h as the time to
compare efficacy of in vitro light exposure of mitochondria
prepared from either mesothelioma or R3230AC xenografts.
Inhibition of cytochrome c oxidase activity (Figure 3) in
Table IV [14C]PII content of subcellular fractions
Sample Mesothelioma R3230AC Liver
Homogenate 377 (56) 404 (93) 2837 (33)
800g SN 635 (88) 497 (20) 2751 (424)
800g Pellet 205 (32) 279 (78) 1767 (201)
8000g SN 398 (52) 316 (67) 1009 (106)
15000g SN 426 (72) 524 (100) 870 (90)
Mitochondria 598 (86) 553 (67) 6468 (529)
Mice bearing either mesothelioma or R3230AC tumours were
administered 6.25 mg kg- '4C-labelled PII 24 h prior to sacrifice and
removal of tumour and liver tissue. Subcellular fractions were
prepared and radioactive content determined as described in
Materials and methods. Data are expressed as d.p.m. x 10-' per mg
of protein as determined for each fraction. Values are the means of
at least four separate determinations and the numbers in parentheses
are the s.e.m. SN, supernatant.
mitochondrial preparations from mesothelioma tissue was
significantly greater than in similar preparations from
R3230AC tumours. The initial rate of enzyme inhibition in
irradiated mitochondria suspensions from mesotheliomas was
0.12% J-1 cm-, whereas enzyme activity in R3230AC
preparations was reduced by 0.08% J-' cm-. No inhibition
of enzyme activity was observed in either tumour mitochon-
drial preparations containing no PPS and exposed to light or
in suspensions containing PPS that were maintained in the
dark. These data suggest a biochemical basis for the observed
difference in response of these xenograft to PDT.
Effects ofPPSphotosensitisation on tumour mitochondria
cytochrome c oxidase in vitro
We exposed tumour mitochondria, prepared from untreated
animals, to PPS (2.5fig ml-') and light in vitro, in an effort
to determine whether any intrinsic differences in photosen-
sitivity ofcytochrome c oxidase between these two neoplasms
would be evident. The data we obtained (Figure 4) demon-
strate no apparent difference in the photosensitivity of this
mitochondrial enzyme for these two tumours.
Uptake of["C]polyhaematoporphyrin in cultured tumour cells
Cultured mesothelioma or R3230AC cells were incubated
with radioactively labelled ['4C]PII, and cellular uptake ofthe
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'4C-labelled material was assessed after 1, 24 and 48 h of
exposure. The amount of porphyrin accumulated in either
cell line by 24 h after the addition of ['4C]PII was equivalent
over a range of 0.5 to 10.0jgml1' of photosensitiser (Figure
5). Results obtained after 1 h or after 48 h incubation of
these tumour cells in vitro (data not shown) demonstrated the
same pattern of [14C]PII uptake as seen after 24 h in
vitro.
Effects ofPPSphotosensitisation on the viability ofcultured
tumour cells
In other experiments, cultured mesothelioma or R3230AC
cells were exposed to various concentrations of PPS and
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either 2.5 or 5.0 min of fluorescent light (see Materials and
methods). Viability was determined at 24 h after light
exposure (Figure 6). The data indicate that the R3230AC
cells were significantly more sensitive (P<0.05) to the higher
doses of PPS (5 or l0jLgml-') than the cultured
mesothelioma cells. These data also show that, despite
equivalent uptake of ['4C]PII by each cell line, photosen-
sitised cytotoxicity was more pronounced in the R3230AC
cell line in vitro. These observations contrast with the
significantly greater efficacy of PDT on mesotheliomas in
vivo.
Histology ofuntreated mesothelioma and R3230AC xenografts
To determine whether the morphology of these tumours
differ, histological preparations were examined. Sections of
the R3230AC mammary carcinoma show a subcutaneous
tumour nodule that is well delineated from the surrounding
loose connective tissue. As seen in a representative section
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Figure 3 Effects of irradiation on the activity of mitochondrial
cytochrome c oxidase measured in suspensions prepared from
tumours 24 h after in vivo administration of 5 mg kg-' PPS.
Details of experimental procedures appear in Materials and
methods. Data are presented as the percentage of initial enzyme
activity (prior to irradiation) and each point represents the
mean ± s.e.m. of at least eight separate experiments performed in
duplicate for mesothelioma (0) or R3230AC (0). Initial cyto-
chrome c oxidase activity was 0.4-0.6fmol cytochrome c
oxidised min-' mg-' mitochondrial protein.
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Figure 5 Total accumulation of['4CIPII ofmesothelioma (0) or
R3230AC (0) cultured cells after a 24 h incubation. Each data
point represents the mean ± s.e.m. (ng of PIl pertLg of total cell
protein) determined from four separate experiments performed in
duplicate.
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Figure 4 Effects of PPS-induced photosensitisation in vitro on
mitochondrial cytochrome c oxidase measured in mesothelioma
(0) or R3230AC (0) mitochondrial suspensions prepared from
tumours implanted in nude mice (see Materials and methods).
Data are presented as the percentage of initial enzyme activity.
Each point represents the mean ± s.e.m. of at least four separate
experiments.
Figure 6 Effects of PPS photosensitisation on cell viability of
either mesothelioma or R3230AC cultured cells. Cells were
exposed to 1, 5 or 10 Igml-' PPS for 24h prior to irradiation
for 2.5 or 5.0 min (see Materials and methods). Data are present-
ed as the percentage of control cell number (not exposed to PII
or light, 0.85-1.0 x 106 cells per well). Each data point represents
the mean ± s.e.m. obtained from at least four separate
experiments performed in duplicate.
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depicted in Figure 7, this well- to moderately differentiated
neoplasm is composed of variably sized glandular forma-
tions, as well as small nests of tumour cells. A thin fibrovas-
cular stromal component, containing a network of capillaries
and small arteriovenous channels, surrounds these tumour
elements. The neoplastic cells range from columnar to
cuboidal forms, which have eosinophillic vesicular cytoplasm,
coarse nuclear chromatin, and one to occasionally multiple
nucleoli. An average of seven mitotic figures is present per
40 x microscopic field. Tumour vessel lumen dimensions are
highly variable, with arteriovenous branches as wide as
60-80 tm in diameter present throughout the tumour
volume.
The H-MESO-1 tumour consists of trabeculae and papil-
lary tumour fronds, which are generally found surrounding a
fibrovascular core. This structure is well depicted in the
section presented in Figure 8. The radius of the viable
tumour cell chords is typically around 140pLm. Beyond the
viable cells, necrotic and degenerating tissue is found using
either haematoxylin and eosin or Masson trichrome stain.
Capillaries supplying the fronds appear quite uniform in
Figure 7 Histological section of an untreated subcutaneous
R3230AC mammary carcinoma excised from a nude mouse. Tis-
sue was stained with haematoxylin and eosin and photographed
under bright-field illumination (field size = 350;Lm x 230 rim).
The clear, unstained regions are variable-sized glandular forma-
tions, and a perfused vessel is present in the centre of the
field.
Figure 8 Histological section of an untreated human
mesothelioma xenograft excised from a nude mouse. The tissue
was stained with Masson trichrome and photographed under
bright-field illumination through a cyan filter (Kodak Wratten,
gelatin no. 44), with the field size identical to that of Figure 7a.
The darkly stained perfused vessel in the centre of the photo-
graphic field supplies a well-defined chord of viable tumour
cells.
diameter (10-15pm), and larger vessels are rare and
confined to the tumour periphery. With the Masson tri-
chrome stain, contrast is excellent between the darkly stained
red cells within the vessel lumen and the surrounding tumour
cells. In some larger tumours, an irregular region of
cavitating necrosis is present near the centre of the lesion.
Focal small clusters of lymphoid inflammatory infiltrate are
found predominantly at the tumour periphery. The neoplastic
cells contain a moderate amount of eosinophilic cytoplasm,
moderately pleomorphic nuclei and a spectrum of indistinct
to multiple prominent nucleoli. Individual tumour cell nec-
rosis and detritus can be found. The average mitotic rate is
approximately 13 per 40 x microscopic field.
Discussion
Patients with diffuse malignant mesothelioma (DMM), a
disease that invades the pleural and peritoneat cavities, have
an expected survival of less than 2 years (Law et al., 1984;
Alberts et al., 1988; Kraup-Hansen & Hansen, 1991). Failure
to achieve favourable response to current treatments may be
due to the inability to detect and treat early disease stages.
The potential offered by PDT, and the fact that DMM
presents as small tumour nodules embedded in a sheet of
malignant cells, suggests that DMM may respond to PDT. In
a previous report (Feins et al., 1990), we found that PDT
inhibited growth of human mesothelioma xenografts, with
response inversely related to fluence rate, i.e. 360 J cm-2
delivered at 50mWcm2 was more effective than the same
fluence administered at fluence rates of 100 or 200 mW cm-2.
Under the conditions employed in this earlier study using
50 mW cm-2, a total fluence of 180 J cm-2 appeared to be as
effective as 270 or 360 J cm-2 in controlling tumour growth.
We found similar results when we extended the observation
time in the present study.
Although we observed a dramatic reduction in tumour
growth rate, which, in comparison with data obtained for the
R3230AC mammary tumours in the rats (Gibson et al.,
1990), showed that the mesothelioma was more sensitive, a
number of questions remained and formed the basis for our
current studies. These questions were: (a) would the suppres-
sion of mesothelioma tumour growth be maintained over a
longer period of time, since our previous report consisted of
an 18 day post-PDT observation time (Feins et al., 1990); (b)
was this mesothelioma peculiarly sensitive to PDT because it
was studied as a xenograft?; (c) was the better response of
mesothelioma to PDT intrinsic to this tumour model?
From the data (Tables I and III, Figure la), it is apparent
that prolonged mesothelioma tumour response was achieved
when irradiation at 50mWcm2 fluence rate was delivered
for total fluences of > 180 Jcm2. Under these conditions,
tumour growth, i.e. tumour volume doubling, occurred at a
median of40 days or longer after PDT (see footnote to Table
II), thus extending the previous observation period by 2-4
times. When the fractionated light treatment regimen that
produced the best R3230AC tumour response in rats (Foster
et al., 1991) was applied to mesothelioma xenografts, striking
responses were observed, with 5/7 mice showing no tumour
volume doubling for observation periods of 208-371 days
after PDT (Table I).
Although the fluence rate dependence of response to PDT
for mesothelioma xenografts was similar to those for
R3230AC mammary tumours in rats (Gibson et al., 1990;
Foster et al., 1991), the tumour volume doubling time of
mesothelioma was extended compared with the mammary
tumour in the rat. These results raise the question ofwhether
the observed difference in response was attributable to some
intrinsic feature of the tumour or the host. To address the
former, we also examined R3230AC tumours grown as
xenografts in mice. These R3230AC xenografts did not res-
pond as well as mesotheliomas and, surprisingly, their res-
ponse was neither fluence nor fluence rate dependent as it
was when they were treated in isologous hosts (Gibson et al.,
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for the different response of the two xenografts, we examined
the time course of ['4C]PII uptake into both tumours; no
difference was observed (Figure 2). However, when mito-
chondria from these xenografts were isolated and irradiated,
cytochrome c oxidase from mesotheliomas was significantly
more photosensitive (Figure 3). One explanation for this
might be that the 'active' components of PPS localised in
different subcellular sites in these two xenografts. This, how-
ever, was ruled out by the measurement of ['4C]PII distribu-
tion among the subcellular fractions (Table IV). This was
further supported by studies of cultured tumour cells in vitro,
in which the uptake of ['4C]PII was essentially the same for
mesothelioma cells and R3230AC (Figure 5). Unexpectedly,
the cytotoxicity of PPS-induced photosensitisation of cells in
culture was not equal for both cell types at various sensitiser
and light doses; in most instances, the R3230AC cells were
significantly more sensitive. Thus, we find that differences in
response to PDT in vivo and photosensitisation in vitro are
not simply related to a difference in photosensitiser concent-
ration or its mitochondrial localisation.
Ris et al. (1993) arrived at a conclusion coincidental with
ours when they found that the tissue concentration of
mTHPP did not correlate with mesothelioma xenograft re-
sponse to PDT. These findings, combined, indicate that the
level of photosensitiser sequestered in malignant tissue may
not ultimately govern tumour response to PDT when study-
ing either one tumour and different doses of photosensitisers
or comparing two tumour types with the same concentration
of intratumoral photosensitisers.
Others have studied various tumours and their response to
PDT but, to our knowledge, none has compared two mor-
phologically different tumours in the same host or the same
tumour in different hosts. Henderson et al. (1985) reported
that 90-100% of EMT6 tumours in Balb/c mice did no.t
recur after PDT, whereas only 13% of RIF tumours in
C3H/HeJ mice did not recur. They attributed this disparity in
response to a difference in the degree of vascular damage,
although they did not rule out occurrence of direct cell
damage in EMT6 tumours. Nahabedian et al. (1988),
confirming those findings, combined PDT with either cis-
platin or adriamycin chemotherapy; adriamycin potentiated
the PDT-induced response of EMT6 tumours but was only
additive in RIF tumours. Here, we observed differences in
the response to PDT of two xenografts of different origin
(the R3230AC rodent mammary adenocarcinoma and a
human H-MESO-1 mesothelioma) in the same host.
One explanation for the disparity in response of these two
tumours to PDT might be that the host haemopoietic re-
sponse differs. Canti et al. (1984) demonstrated increased
marrow cellularity and splenic hyperplasia after various mul-
tiple daily injections of 8-75 mgkg-' haematoporphyrin
derivative (HpD) without exposure of the host to light.
Similar haemopoietic responses were observed by Henderson
and Stewart (1992) and Levy et al. (1992) using Photofrin II.
Those studies imply that there may be haemopoietic stimula-
tion resulting from the porphyrin photosensitiser either in
vitro or in vivo and that this stimulation may occur both in
the dark and after exposure to light. In this present study, we
utilised the nude mouse to xenograft both tumour types, and
we would expect little difference in haemopoietic response
because of a number of factors. Growth ofboth tumours was
not significantly different from growth of xenografts in the
nude mouse or from the growth of R3230AC in its isologous
host, the Fischer female rats. Administration of 5 mgkg-'
PPS was expected to elicit the same response, particularly
since photosensitiser retention and distribution in the xeno-
grafted tumours were equivalent.
The results of the present study strongly suggest that PDT
response in these systems cannot be predicted on the basis of
easily identified 'cell-specific' or 'host-specific' criteria.
Rather, it appears that complex factors involving tumour
cell-host interactions are important and difficult to analyse.
R3230AC cells, while more responsive to PDT than H-
MESO-1 cells in vitro, are clearly less responsive to equiva-
lent PDT treatment regimens in both isologous hosts and
nude mice in vivo. Hence, sensitivity to PDT in vitro is not an
invariable predictor of the tumour sensitivity in vivo. Further,
these two tumour cell lines, when grown as subcutaneous
transplants in the same host, exhibit significantly different
responses to PDT. Thus, we have been unable to identify any
obvious feature of the host as being responsible for tumour
response.
The complexity of this is further illustrated by the fact that
the R3230AC tumour exhibits a different fluence and fluence
rate dependence in the two host systems. In the Fischer rat,
significant prolongation of tumour regrowth is observed
when reduced fluence rate or fractionated irradiation pro-
tocols are employed, indicating that therapy-induced oxygen
consumption is an important limiting factor in this system.
On the other hand, no such fluence rate dependence is
observed for this tumour when treated as a xenograft in the
nude mouse. It is possible that the R3230AC elicits a better
vascular supply when grown in the mouse and that this
better perfusion is responsible for the absence of a fluence
rate effect (Foster & Gao, 1992). However, it is also possible
that some other factor plays the predominant limiting role.
If, for example, the intratumoral distribution of PPS is
significantly more heterogeneous in the xenograft system than
it is in the isologous host, it may not be possible to influence
the tumour response to PDT by reduction in the rate of
photochemical oxygen consumption. Differences in intra-
tumoral photosensitiser distribution would not be measured
by the '4C uptake studies and biochemical assays reported
here, since these represent spatial averages over the entire
tumour volume. Whatever the mechanism governing the lack
of a fluence rate dependence for response of the R3230AC in
the mouse, it is clear that it cannot be attributable to an
intrinsic property of the murine host, since pronounced
fluence rate effects are observed in the mesothelioma grown
in this host system.
Examination of histological sections of the two xenografts
demonstrates that their morphologies are very different.
Generally, the mesothelioma appears to consist of a uniform
distribution of cells and vessels. The R3230AC, on the other
hand, demonstrates little uniformity in either cellular dist-
ribution or vessel location and diameter. Whether these struc-
tural variations are the basis for the significant differences in
response of these tumours to PDT is, as yet, unknown.
In conclusion, we find that the sensitivity of a human
mesothelioma xenograft to PDT is dependent on total fluence
and inversely dependent on incident fluence rate. These
mesothelioma xenografts are significantly more responsive to
PDT at a lower fluence rate and high total fluences than are
rodent R3230AC tumour xenografts in the same host. The
basis for the observed difference in sensitivity of these two
xenografts could not be attributed directly to photosensitiser
uptake or its subcellular localisation or to any intrinsic sen-
sitivity studied here.
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